Abstract
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003. By September 2002, the compound had entered phase III trials for smoking cessation, and these trials were ongoing in September 2003.
MeSH terms
-
Animals
-
Anti-Obesity Agents / chemical synthesis
-
Anti-Obesity Agents / chemistry
-
Anti-Obesity Agents / pharmacokinetics
-
Antipsychotic Agents / chemical synthesis
-
Antipsychotic Agents / chemistry
-
Antipsychotic Agents / pharmacokinetics
-
Appetite Depressants / chemical synthesis
-
Appetite Depressants / chemistry
-
Appetite Depressants / pharmacokinetics
-
Clinical Trials as Topic
-
Humans
-
Obesity / drug therapy
-
Piperidines / chemical synthesis
-
Piperidines / chemistry*
-
Piperidines / pharmacokinetics
-
Potassium Channel Blockers / chemical synthesis
-
Potassium Channel Blockers / chemistry
-
Potassium Channel Blockers / pharmacokinetics
-
Pyrazoles / chemical synthesis
-
Pyrazoles / chemistry*
-
Pyrazoles / pharmacokinetics
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
-
Rimonabant
-
Smoking Cessation
-
Structure-Activity Relationship
Substances
-
Anti-Obesity Agents
-
Antipsychotic Agents
-
Appetite Depressants
-
Piperidines
-
Potassium Channel Blockers
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Rimonabant